NfL

Ozanimod Reduces Serum Neurofilament Light Chain (NfL) and Glial Fibrillary Acidic Protein (GFAP) and Modulates Innate and Adaptive Immunity in Patients with Low-to-Moderate Activity Relapsing-Remitting Multiple Sclerosis

Study Overview The research investigates the effects of ozanimod, an oral medication, on key biomarkers associated with neurodegeneration and inflammation […]

Ozanimod Reduces Serum Neurofilament Light Chain (NfL) and Glial Fibrillary Acidic Protein (GFAP) and Modulates Innate and Adaptive Immunity in Patients with Low-to-Moderate Activity Relapsing-Remitting Multiple Sclerosis Read Post »

Comparative Analysis of Mouse CSF Proteins in Experimental Autoimmune Encephalomyelitis Model and Cuprizone-Induced Demyelination Model by Olink Proteomics

Study Overview This research investigates protein alterations in the cerebrospinal fluid (CSF) using two distinct models of demyelination: Experimental Autoimmune

Comparative Analysis of Mouse CSF Proteins in Experimental Autoimmune Encephalomyelitis Model and Cuprizone-Induced Demyelination Model by Olink Proteomics Read Post »

Relevance of serum neurofilament light chain determination as a biomarker in multiple sclerosis. Consensus of the Spanish Society of Neurology’s Study Group on Multiple Sclerosis and Related Neuroimmune Diseases

Relevance of Neurofilament Light Chain Neurofilament light chain (NfL) plays a crucial role in the assessment of neurodegenerative diseases, including

Relevance of serum neurofilament light chain determination as a biomarker in multiple sclerosis. Consensus of the Spanish Society of Neurology’s Study Group on Multiple Sclerosis and Related Neuroimmune Diseases Read Post »

Scroll to Top